Founded in 2020 and based in San Carlos, California, IHP Therapeutics applies Glycobiology to develop targeted treatments for cancer and hemolytic diseases. Their pipeline of glycan therapeutics focuses on immune modulation, inflammation, and infection. By leveraging Glycobiology, IHP Therapeutics aims to overcome innate immune responses in gene therapy applications and provide innovative solutions for hematological diseases and cancer treatment.